Trial reportJournal of cancer research and clinical oncology2021
Effects of a patient-tailored integrative oncology intervention in the relief of pain in palliative and supportive cancer care.
Trial report in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Integrative oncology for young adults with cancer: A prospective pragmatic controlled trial.Medical oncology (Northwood, London, England) · 2026Trial
- A randomized-controlled trial assessing the effect of intraoperative acupuncture on anesthesia-related parameters during gynecological oncology surgery.Journal of cancer research and clinical oncology · 2023Trial
- Impact of a combined integrative oncology and palliative care program on quality of life of patients with advanced cancer.Medical oncology (Northwood, London, England) · 2021Trial
- In Vitro Anti-Glioblastoma Activity of a Novel Pt(IV)-Ganoderic Acid A Conjugate.International journal of molecular sciences · 2026Article
- Diabetes Comorbidity and Quality of Life in Patients with Cancer: A Prospective Study in an Integrative Oncology Setting.Journal of clinical medicine · 2025Article
- Fine-tuning the needle: analysis of acupuncturist response to alarming events during gynecological oncology surgery.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Integrative Medicine for Cancer-Related Pain: A Narrative Review.Healthcare (Basel, Switzerland) · 2024Review
- Identifying cultural, demographic, personal health and cancer-related barriers to integrative oncology care: a retrospective case-cohort study.Journal of cancer research and clinical oncology · 2023Article
- Personalized Medicine in Cancer Pain Management.Journal of personalized medicine · 2023Review
- Sensing the lightness: a narrative analysis of an integrative medicine program for healthcare providers in the COVID-19 department.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Acupuncture for cancer pain: an evidence-based clinical practice guideline.Chinese medicine · 2022Review
- Adherence to Integrative Care, Oncology Healthcare Utilization, Opioid Use and Hospitalization.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CONTEXT AND
objectivesThe present study examined the impact of an integrative oncology treatment program in the relief of pain in patients undergoing chemotherapy and/or palliative care.
methodsIn this pragmatic prospective controlled study, patients undergoing chemotherapy and/or palliative care were referred by their oncology healthcare providers to an integrative physician (IP) consultation, followed by weekly integrative treatments. Patients attending ≥ 4 sessions during the first 6 weeks of the study were considered to be highly adherent to integrative care (AIC). Pain was assessed at baseline and at 6 and 12 weeks using the ESAS (Edmonton Symptom Assessment Scale) and EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) tools.
resultsOf 815 eligible patients, 484 (59.4%) were high-AIC and 331 low-AIC. Mean pain scores decreased significantly from baseline to 6 and 12 weeks in both groups. However, ESAS and EORTC pain scores improved significantly more in the high-AIC group at 6 weeks (p= 0.008), though not at 12 weeks. Between-group analysis of participants undergoing adjuvant/neo-adjuvant chemotherapy showed higher pain reduction in the high-AIC group at 6 weeks (ESAS, p = 0.006; EORTC, p = 0.046), as was the case with patients receiving palliative care (ESAS p = 0.04; EORTC p = 0.056).
conclusionsHigh adherence to integrative care was found to be associated with a greater effect on pain relief at 6 weeks but not at 12 weeks in patients undergoing chemotherapy and/or palliative care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.